Please login to the form below

Not currently logged in
Email:
Password:

Pfizer phase III Lyrica success

Pfizer has recorded positive results in a phase III trial of fibromyalgia treatment Lyrica

Pfizer has recorded positive results in a phase III trial of Lyrica (pregabalin), a potential new treatment for fibromyalgia -  a disabling disorder that adversely affects quality of life.

The study demonstrated a statistically significant reduction in the endpoint mean pain score recorded by participants, with the drug demonstrating efficacy and safety.

The drug was compared to placebo, with 501 subjects involved across 45 investigative sites in Japan.

"We are pleased with the top-line results of this study and look forward to more fully understanding the potential benefits that Lyrica may bring to fibromyalgia patients in Japan," said Dr Akihisa Harada, vice president, head of development, at Pfizer Japan.

The most common adverse events in the study were somnolence, dizziness, weight increased, constipation, feeling abnormal, edema peripheral and blurred vision.

7th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics